Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 647-652

  Zannetti, Beatrice Anna ^a   Zamagni, Elena ^a   Santostefano, Marisa ^a   De Sanctis, Lucia Barbara ^a   Tacchetti, Paola ^a   Mancini, Elena ^a   Pantani, Lucia ^a   Brioli, Annamaria ^a   Rizzo, Raffaella ^a   Mancuso, Katia ^a   Rocchi, Serena ^a   Pezzi, Annalisa ^a   Borsi, Enrica ^a   Terragna, Carolina ^a   Marzocchi, Giulia ^a   Santoro, Antonio ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; CREATININE; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONCENTRATION (PARAMETERS); CONSOLIDATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH CUT OFF HEMODIALYSIS; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; KIDNEY TUBULE DISORDER; LIGHT CHAIN; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REFERENCE VALUE; SERUM FREE LIGHT CHAIN; SEVERE RENAL IMPAIRMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; REMISSION; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INDUCTION CHEMOTHERAPY; KIDNEY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL ANALYSIS;

EID: 84931864027     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24035     Document Type: Article

References (32)

1. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the international myeloma working group. J Clin Oncol 2010;28:4976-4984.
2. Gaballa MR, Laubach JP, Schlossman RL, et al. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol 2012;5:51-66.
3. Chanan-Khan AA, San Miguel JF, Jagannath S, et al. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res 2012;18:2145-2163.
4. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2011;8:43-51.
5. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002-Medical research council adult leukaemia working party. J Clin Oncol 2005;23:9219-9226.
6. Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: Multicenter study in 198 consecutive patients. Eur J Haematol 2009;83:519-527.
7. Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395-1397.
8. Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014;25:195-200.
9. Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92:1411-1414.
10. Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 2010;28:4635-4641.
11. Breitkreutz I, Heiss C, Perne A, et al. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure. Bone Marrow Transpl 2014;49:1371-1375.
12. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-895.
13. Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-754.
14. Hutchison CA, Heyne N, Airia P, et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 2012;27:3823-3828.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982;5:649-655.
16. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1. Blood 2011;117:4691-4695.
17. Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55:622-627.
18. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010;376:2075-2085.
19. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9-19.
20. Santostefano M, Zanchelli F, Zaccaria A, et al. The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 2005;18:659-675.
21. Ying WZ, Wang PX, Aaron KJ, et al. Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 2011;117:1301-1307.
22. Uttervall K, Andreasson J, Liwing J, et al. Is renal impairment still a poor prognostic marker in myeloma care? A population based study including 1542 patients. ASH Ann Meet Abstr 2012;120:5033.
23. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013;27:423-429.
24. Jagannath S, Barlogie B, Berenson JR, SUMMIT/CREST Investigators, et al. Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195-1200.
25. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 2007;109:2604-2606.
26. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27:6086-6093.
27. Scheid C, Sonneveld P, Schmidt-Wolf IGH, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: A subgroup analysis from the HOVON-65/GMMG-hd4 trial. Haematologica 2014;99:148-154.
28. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175-1180.
29. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 2005;143:77-84.
30. Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011;364:2365-2366.
31. Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials 2008;9:55-62.
32. Sinisalo M, Silvennoinen R, Wirta O. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy. Am J Hematol 2012;87:640.